LENZ Therapeutics, Inc. (LENZ) stock
LENZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3046% below fair value
$4.13+0.04 (+0.98%)
Close on Nov 13, 2026Market cap $129.77MP/E –Yield –
LENZ Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
LENZ Therapeutics's ebitda for the twelve months ending Jun 30, 2026 was -$135.20M. For fiscal 2025 it was -$90.85M. The highest annual figure on record is -$13.38M in fiscal 2020.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$90.85M | – |
| FY2024 | Dec 31, 2024 | -$58.55M | – |
| FY2023 | Dec 31, 2023 | -$72.41M | – |
| FY2022 | Dec 31, 2022 | -$103.29M | – |
| FY2021 | Dec 31, 2021 | -$59.71M | – |
| FY2020 | Dec 31, 2020 | -$13.38M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$34.06M | – |
| Q1 FY2026 | Mar 31, 2026 | -$44.02M | – |
| Q4 FY2025 | Dec 31, 2025 | -$38.36M | – |
| Q3 FY2025 | Sep 30, 2025 | -$18.76M | – |
| Q2 FY2025 | Jun 30, 2025 | -$16.84M | – |
| Q1 FY2025 | Mar 31, 2025 | -$16.90M | – |
| Q4 FY2024 | Dec 31, 2024 | -$15.20M | – |
| Q3 FY2024 | Sep 30, 2024 | -$12.94M | – |
| Q2 FY2024 | Jun 30, 2024 | -$14.33M | – |
| Q1 FY2024 | Mar 31, 2024 | -$16.08M | – |
| Q4 FY2023 | Dec 31, 2023 | -$24.99M | – |
| Q3 FY2023 | Sep 30, 2023 | -$19.86M | – |
| Q2 FY2023 | Jun 30, 2023 | -$14.96M | – |
| Q1 FY2023 | Mar 31, 2023 | -$12.61M | – |
| Q4 FY2022 | Dec 31, 2022 | -$26.07M | – |
| Q3 FY2022 | Sep 30, 2022 | -$25.50M | – |
| Q2 FY2022 | Jun 30, 2022 | -$26.20M | – |
| Q1 FY2022 | Mar 31, 2022 | -$25.52M | – |
| Q4 FY2021 | Dec 31, 2021 | -$18.61M | – |
| Q3 FY2021 | Sep 30, 2021 | -$14.40M | – |
| Q2 FY2021 | Jun 30, 2021 | -$17.42M | – |
| Q1 FY2021 | Mar 31, 2021 | -$9.28M | – |
| Q4 FY2020 | Dec 31, 2020 | -$8.25M | – |
See a number that looks wrong?